Business growth

Pfizer and BioNTech began a 2/3 clinical study phase of a joint mRNA-based coronavirus vaccine - BNT162b2. A global study involving up to 30,000 volunteers aged 18 to 85 years began in the USA and is expected to cover about 120 clinical research centers worldwide except China.